| [1] |
Liu FF, Shi W, Done SJ, et al. Identification of a low-risk luminal A breast cancer cohort that may not benefit from breast radiotherapy [J].J Clin Oncol,2015,33(18):2035-2040.
|
| [2] |
Slamon D, Eiermann W, Robert N, et al. Ten year follow-up of the BCIRG-006 trial comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC-T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 +early breast cancer patients [EB/OL]. [2016-01-05]. http:/ /www. abstracts2view. com/sabcs15/view.php? nu=SABCS15L_1030&terms.
|
| [3] |
Toi M, Lee SJ,Lee ES,et al. A phase Ⅲtrial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X,JBCRG-04) [EB/OL]. [2016-01-05]. http:/ /www. abstracts2view. com/sabcs15/view.php? nu=SABCS15L_1229&terms.
|
| [4] |
von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto;GBG 66):a randomised phase 2 trial [J].Lancet Oncol,2014,15(7):747-756.
|
| [5] |
Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvant chemotherapy in stage Ⅱ-Ⅲtriple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance) [J]. Ann Surg,2015,262(3):434-439.
|
| [6] |
No authors listed. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial [J]. JAMA Oncol, 2015,1(4):544.
|
| [7] |
Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumabbased adjuvant therapy in patients with HER2-positive breast cancer(ExteNET): a multicentre, randomised, double-blind, placebocontrolled, phase 3 trial [EB/OL]. [2016-01-05]. http:/ /www.sciencedirect.com/science/article/pii/S1470204515005513.
|
| [8] |
Boyraz B, Sendur MA, Aksoy S, et al. Trastuzumab emtansine(T-DM1) for HER2-positive breast cancer [J]. Curr Med Res Opin,2013,29(4):405-414.
|
| [9] |
Hein A, Lambrechts D, von Minckwitz G, et al. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase ⅢGeparQuinto study[J]. Int J Cancer,2015,137(12):2981-2988.
|
| [10] |
Vansteenkiste JF, Canon JL, Braud FD, et al. Safety and efficacy of Buparlisib (BKM120) in patients with PI3K pathway-activated nonsmall cell lung cancer:results from the phase ⅡBASALT-1 study [J].J Thorac Oncol,2015,10(9):1319-1327.
|
| [11] |
Dirix LY, Takacs I, Nikolinakos P, et al. Avelumab(MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial [EB/OL]. [2016-01-05]. http:/ /www. abstracts2view. com/sabcs15/view.php? nu=SABCS15L_984&terms.
|
| [12] |
Adams S, Diamond J,Hamilton E,et al. Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer [EB/OL].[2016-01-05]. http:/ /www. abstracts2view. com/sabcs15/view. php?nu=SABCS15L_1208&terms.
|